Welcome to our dedicated page for Accendra Health news (Ticker: ACH), a resource for investors and traders seeking the latest updates and insights on Accendra Health stock.
Accendra Health, Inc. reports developments in home-based healthcare products, technology and services delivered through the Apria and Byram Healthcare brands. The company connects patients, providers and insurers across diabetes supplies, sleep health, respiratory care, wound care, urology, ostomy and related patient support categories.
News for ACH centers on quarterly results, guidance, continuing-operations performance after the completed sale of the Products & Healthcare Services business, NYSE ticker changes, debt reduction, maturity extension and other balance-sheet actions tied to its home healthcare platform.
Accendra Health (ACH) updated investors on capital allocation and CEO succession plans. The company decided not to implement a previously contemplated at-the-market equity issuance program, stating it was never intended as a liquidity source and its cancellation will not affect results of operations or published guidance.
According to Accendra Health, liquidity is supported by increasing cash collections, progress on resolving payor collection issues, and an undrawn $300 million revolving credit facility, which it does not expect to use except for working capital fluctuations. The company closed the sale of one non-core asset in Q3 and expects a second to close by year-end, for combined cash proceeds of about $45 million with de minimis impact on Adjusted EBITDA. The board expects to name a successor to CEO Mr. Pesicka by mid-September 2026, ahead of his planned retirement by end-2026, with him remaining as CEO until the transition and then serving in an advisory role.
Accendra Health (NYSE: ACH) announced that its board adopted a Section 382 Rights Agreement, called a Tax Asset Preservation Plan, effective August 10, 2026. The plan is intended to help preserve the company’s net operating loss carryforwards (NOLs) and other tax attributes by discouraging ownership changes under Section 382 of the Internal Revenue Code.
The plan aims to deter any person or group from acquiring 4.9% or more of Accendra Health’s outstanding common stock. If an “ownership change” occurs, holders of rights (other than the triggering person) may purchase common shares at a 50% discount or the company may exchange each right for one share. The plan is scheduled to remain in effect until August 10, 2029, unless terminated earlier. Accendra Health will also host its previously announced second quarter 2026 earnings conference call on August 10, 2026 at 8:00 a.m. ET, with access via toll-free and webcast options.
Accendra Health (NYSE: ACH) reported second quarter 2026 continuing-operations net revenue of $613.2 million, down from $681.9 million in 2Q25, with a GAAP loss from continuing operations of $89.1 million versus $83.8 million a year earlier. Adjusted EBITDA was $60.1 million (2Q25: $96.6 million) and free cash flow was -$25.1 million (2Q25: $15.2 million). The company reduced outstanding debt by $385 million and said it has eliminated well over $125 million of annualized operating expense tied to a large commercial payor exit.
For full-year 2026, Accendra Health guides to net revenue of $2.45–$2.55 billion, adjusted EBITDA of $300–$320 million, and free cash flow of breakeven to slightly positive. CEO Edward A. Pesicka has informed the board of his intention to retire by the end of 2026.
Accendra Health (NYSE: ACH) announced that President and CEO Edward A. Pesicka plans to retire by the end of 2026 and will leave the Board of Directors before year-end 2026. The Board has an established succession planning process and has already identified potential CEO candidates, and will now conduct a comprehensive search.
According to the company, Pesicka may serve in an advisory role after retirement to support a smooth transition. Management highlighted his role in stabilizing the company, expanding PPE production during the pandemic, executing the divestiture of Owens & Minor, a balance sheet optimization transaction, and the transformation into Accendra Health. The company also reminded investors of its second-quarter 2026 earnings conference call on August 10, 2026, at 8:00 a.m. ET.
Accendra Health (ACH) announced leadership changes in Information Technology and Procurement to support its strategy as a pure play home-based care organization. Nicholas (Nick) Piecora was promoted in May to Senior Vice President & Chief Information Officer, reporting to President & CEO Edward Pesicka. Agnes Ansay has been appointed Vice President & Chief Procurement Officer, effective immediately, reporting to Executive Vice President & CFO Jonathan Leon.
According to Accendra Health, Piecora will focus on leveraging technology and automation to enhance home-based care, customer experience, and operational performance. Ansay will lead the Procurement organization, drawing on more than 10 years of global procurement leadership across large, complex enterprises.
Accendra Health (NYSE: ACH) plans to release its second quarter 2026 financial results on Monday, August 10, 2026, before NYSE trading begins. The company will host an investor conference call at 8:00 a.m. EDT, with phone and webcast access plus a replay available.
Accendra Health (NYSE:ACH) reported final results of its note exchange offers and consent solicitations. As of 5:00 p.m. New York time on June 23, 2026, approximately 99.9% of 4.500% 2029 Notes and 99.2% of 6.625% 2030 Notes were tendered.
According to Accendra Health, it issued or expects to issue $213.0 million of First Lien Notes and $698.1 million of Second Lien Notes in exchange, plus $326.25 million of First Lien Notes as new money, totaling $539.25 million First Lien Notes. The unregistered New Notes were offered only to Eligible Holders under Rule 144A and Regulation S.
Summary not available.
Accendra Health (NYSE: ACH) launched exchange offers for all outstanding 4.500% notes due 2029 and 6.625% notes due 2030 into new 9.000% first-lien 2032 notes and 9.750% second-lien 2033 notes, plus a $326.25 million new-money first-lien issuance.
According to Accendra Health, commitment parties agreed to tender approximately all 2029 notes and about 83% of 2030 notes and to backstop up to $326.25 million of first-lien notes. Early exchange and withdrawal deadlines are June 9, 2026; final expiration is June 22, 2026.
Accendra Health (NYSE: ACH) reported first quarter 2026 results and announced a >$1.5 billion balance sheet optimization backed by existing creditors. The transaction is expected to reduce debt, pay off 2027 maturities, and extend its revolving credit facility.
Q1 2026 continuing operations showed net revenue of $627.8 million, GAAP loss from continuing operations of $6.5 million ($0.08 per share), non-GAAP adjusted net loss of $3.1 million, adjusted EBITDA of $58.4 million, and free cash flow of -$2.0 million. Full-year 2026 net revenue and adjusted EBITDA guidance were reaffirmed.